Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc.（DAWN）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · DAWN · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
13
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Day One Biopharmaceuticals, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
DAWN 季度内部人买卖趋势
DAWN 内幕交易卖出 · DAWN 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · DAWN CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
DAWN 高管卖出股份 · DAWN 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Apr 23, 2026 | AI Day1 LLC 10 percent owner | Other | 12,929,322 | $277.98M⚡ | Form 4 |
| Apr 23, 2026 | Bender Jeremy CHIEF EXECUTIVE OFFICER · Director | Other | 808,285 | $81 | Form 4 |
| Apr 23, 2026 | VASCONCELLES MICHAEL Head of Research and Dev. | Other | 4,397 | $0 | Form 4 |
| Apr 23, 2026 | York Charles N II COO and CFO | Other | 312,025 | $31 | Form 4 |
| Apr 23, 2026 | Dubow Adam Gen Counsel & Secretary | Other | 72,694 | $7 | Form 4 |
| Apr 23, 2026 | Holles Natalie C. Director | Other | 57,310 | $6 | Form 4 |
| Apr 23, 2026 | Ramasastry Saira Director | Other | 40,485 | $4 | Form 4 |
| Apr 23, 2026 | Josey John A. Director | Other | 72,292 | $7 | Form 4 |
| Apr 23, 2026 | Merendino Lauren Chief Commercial Officer | Other | 60,157 | $6 | Form 4 |
| Feb 15, 2026 | Merendino Lauren Chief Commercial Officer | Option | 4,625 | — | Form 4 |
| Feb 15, 2026 | Merendino Lauren Chief Commercial Officer | Option | 3,687 | — | Form 4 |
| Feb 17, 2026 | Merendino Lauren Chief Commercial Officer | Sale | 5,814 | $67K | Form 4 |
| Feb 15, 2026 | Merendino Lauren Chief Commercial Officer | Option | 3,688 | — | Form 4 |
| Feb 15, 2026 | Merendino Lauren Chief Commercial Officer | Option | 3,162 | — | Form 4 |
| Feb 15, 2026 | Dubow Adam Gen Counsel & Secretary | Option | 4,375 | — | Form 4 |
| Feb 15, 2026 | Dubow Adam Gen Counsel & Secretary | Option | 3,687 | — | Form 4 |
| Feb 17, 2026 | Dubow Adam Gen Counsel & Secretary | Sale | 6,395 | $74K | Form 4 |
| Feb 15, 2026 | Dubow Adam Gen Counsel & Secretary | Option | 3,688 | — | Form 4 |
| Feb 15, 2026 | Dubow Adam Gen Counsel & Secretary | Option | 1,750 | — | Form 4 |
| Feb 15, 2026 | Dubow Adam Gen Counsel & Secretary | Option | 2,963 | — | Form 4 |
| Feb 15, 2026 | York Charles N II COO and CFO | Option | 7,875 | — | Form 4 |
| Feb 17, 2026 | York Charles N II COO and CFO | Sale | 6,065 | $70K | Form 4 |
| Feb 15, 2026 | York Charles N II COO and CFO | Option | 6,625 | — | Form 4 |
| Feb 15, 2026 | York Charles N II COO and CFO | Option | 6,625 | — | Form 4 |
| Feb 15, 2026 | York Charles N II COO and CFO | Option | 2,250 | — | Form 4 |
Bender Jeremy
CHIEF EXECUTIVE OFFICER · Director
日期
Apr 23
股数
808,285
均价
$0.00
总金额
$81
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 DAWN 内幕交易
DAWN 内幕交易
Day One Biopharmaceuticals, Inc.（DAWN）内幕交易数据来源于公司内部人（包括Bender Jeremy (CHIEF EXECUTIVE OFFICER · Director), Dubow Adam (Gen Counsel & Secretary), York Charles N II (COO and CFO)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。DAWN内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Day One Biopharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
DAWN 内幕交易 · 5个问题Day One Biopharmaceuticals, Inc.（DAWN）的内部人包括高管和董事，如Bender Jeremy (CHIEF EXECUTIVE OFFICER · Director), Dubow Adam (Gen Counsel & Secretary), York Charles N II (COO and CFO)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026